0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Cystoid Macular Edema Secondary to Albumin-Bound Paclitaxel Therapy FREE

Stacy V. Smith, BA; Matthew S. Benz, MD; David M. Brown, MD
Arch Ophthalmol. 2008;126(11):1605-1606. doi:10.1001/archopht.126.11.1605.
Text Size: A A A
Published online

Cystoid macular edema (CME) without capillary leakage is a rare subcategory of CME recently associated with the taxane drugs docetaxel (Taxotere; Sanofi-Aventis US LLC, Bridgewater, New Jersey) and paclitaxel (Taxol; Bristol-Meyers Squibb Co, Princeton, New Jersey).13 Protein-bound paclitaxel (Abraxane; Abraxis BioScience Inc, Los Angeles, California) is an albumin-stabilized nanoparticle formulation of paclitaxel reported to be more effective and better tolerated than standard paclitaxel.4 We report for the first time to our knowledge a case of profound CME with minimal fluorescein leakage secondary to treatment with the newer albumin-bound paclitaxel, which resolved on discontinuation of the drug.

A 56-year-old white woman had a 2-month history of decreased vision in both eyes with no other associated symptoms. She had been receiving protein-bound paclitaxel for approximately 2.5 years at a dosage of 400 mg every 3 weeks concomitant with trastuzumab (Herceptin; Genentech Inc, South San Francisco, California) for stage IV breast cancer, with the last intravenous infusion 3 weeks prior to her initial visit. Visual acuity corrected to 20/80 OD and 20/60 OS. Anterior segment examination revealed no inflammation and 1+ nuclear sclerosis in both eyes. Dilated fundus examination showed marked CME bilaterally. Spectral-domain optical coherence tomography (Carl Zeiss Meditec Inc, Dublin, California) determined the central retinal thickness to be 630 μm OD and 585 μm OS (Figure 1). Profound CME with well-defined septa was evident in the outer plexiform layer, with cystic changes clearly visible throughout all layers. Fluorescein angiography results were normal until late frames, where minimal leakage could be discerned centrally (Figure 2). The patient discontinued protein-bound paclitaxel therapy immediately but continued to receive trastuzumab.

Place holder to copy figure label and caption
Figure 1.

Spectral-domain optical coherence tomographic imaging reveals profound cystoid macular edema at the initial visit with intraretinal cysts primarily in the outer retinal layers of the right eye (A), and the patient exhibited complete resolution at the 3-month follow-up (B). The left eye had similar findings.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Fluorescein angiographic images reveal normal vascular filling in early frames of the right eye (A) and only minimal late leakage evident in the late frames (B). The left eye had similar findings.

Graphic Jump Location

On follow-up 4 weeks later, the patient noted marked improvement in her visual acuity (20/60 OU uncorrected) and ophthalmic examination confirmed dramatic reduction of the CME. Spectral-domain optical coherence tomography documented the central retinal thickness in the right eye to be 352 μm, a reduction of 278 μm. Similarly, the left eye reduced by 291 μm to a central retinal thickness of 294 μm. Only small cystic changes remained. At the 3-month follow-up, the patient's best-corrected visual acuity had improved to 20/20 OU and spectral-domain optical coherence tomography revealed complete resolution of CME with central retinal thickness of 252 μm OD and 261 μm OS (Figure 1).

Our findings demonstrate that albumin-bound paclitaxel, like other taxanes, can result in CME, which is reversible on cessation of protein-bound paclitaxel therapy. Interestingly, there has been another documented case of CME in a patient receiving trastuzumab concurrent with taxane therapy.3 However, it does not appear to be related to the cause of CME in our case as our patient's condition improved despite continued trastuzumab therapy.

The pathogenesis of CME without capillary leakage remains unclear. The slight amount of leakage on late fluorescein angiographic frames in our case implies a partial compromise of the blood-retinal barrier. With a partial compromise, smaller molecules and proteins may diffuse out more readily than the larger fluorescein molecules.2 Fluorescein would diffuse into the extracapillary space at a much slower rate, resulting in the findings of no or very slight leakage on late fluorescein angiographic frames. A previous report suggested that the mechanism of drug-induced CME without capillary leakage is similar to that of fluid retention syndrome.2 Our patient, however, had no systemic evidence of fluid retention. There is no other explanation for why taxane therapy caused CME in this patient, especially after 2.5 years of treatment.

It was hoped that this new nanoparticle protein-bound formulation of paclitaxel would have fewer adverse effects than the non–protein-bound version. However, it appears that all types of taxane therapy can cause angiographically atypical CME. If the association is recognized, the condition appears to be reversible on discontinuation of therapy.

Correspondence: Dr Brown, Vitreoretinal Consultants, 6560 Fannin St, Ste 750, Houston, TX 77030 (dmbmd@houstonretina.com).

Financial Disclosure: None reported.

Teitelbaum  BATresley  DJ Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 2003;80 (4) 277- 279
PubMed Link to Article
Telander  DGSarraf  D Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 2007;22 (3) 151- 153
PubMed Link to Article
Joshi  MMGarretson  BR Paclitaxel maculopathy. Arch Ophthalmol 2007;125 (5) 709- 710
PubMed Link to Article
Gradishar  WJTjulandin  SDavidson  N  et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23 (31) 7794- 7803
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Spectral-domain optical coherence tomographic imaging reveals profound cystoid macular edema at the initial visit with intraretinal cysts primarily in the outer retinal layers of the right eye (A), and the patient exhibited complete resolution at the 3-month follow-up (B). The left eye had similar findings.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Fluorescein angiographic images reveal normal vascular filling in early frames of the right eye (A) and only minimal late leakage evident in the late frames (B). The left eye had similar findings.

Graphic Jump Location

Tables

References

Teitelbaum  BATresley  DJ Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 2003;80 (4) 277- 279
PubMed Link to Article
Telander  DGSarraf  D Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 2007;22 (3) 151- 153
PubMed Link to Article
Joshi  MMGarretson  BR Paclitaxel maculopathy. Arch Ophthalmol 2007;125 (5) 709- 710
PubMed Link to Article
Gradishar  WJTjulandin  SDavidson  N  et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23 (31) 7794- 7803
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 12

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles